En‐Chi Hsu

Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis

Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential Molecular Indicator in Prostate Cancer

Circulating extracellular vesicles in serum carry Trop2 marker for prostate cancer liquid biopsy and clinical care

UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

Abstract 6574: UCHL1 is a molecular indicator and a therapeutic target for neuroendocrine carcinomas

Abstract 5968: CDC7 is a targetable regulator of advanced prostate cancer

Abstract 6962: Shed Trop2 drives prostate cancer progression and Trop2 is a novel tissue prognostic biomarker and a candidate urinary marker for prostate cancer

Data from <i>In Vivo</i> Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification

SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

Abstract 2324: A novel oncogene mediated metabolic gene signature predicts breast cancer outcome

Abstract 81: Trop2 regulates prostate cancer growth and metastasis through distinct molecular mechanisms

Gold Nanoclusters for NIR‐II Fluorescence Imaging of Bones

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1

Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer

Bone Imaging: Gold Nanoclusters for NIR‐II Fluorescence Imaging of Bones (Small 43/2020)

The Exosome Total Isolation Chip

Abstract 4917: Therapeutic inhibition of Notch1 in metastatic prostate cancer

Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer